Viking Therapeutics (NASDAQ: VKTX) is emerging as a potential game-changer in the burgeoning obesity treatment market, which could reach nearly $100 billion by the end of the decade. With its leading candidates in late-stage clinical trials, including the injectable VK2735, Viking is positioned to capitalize on the explosive demand for weight loss drugs, currently dominated by Eli Lilly and Novo Nordisk. The recent completion of enrollment for VK2735’s phase 3 trial ahead of schedule highlights significant patient interest and market potential.

The financial implications for Viking are substantial, especially as existing drugs like Lilly’s Zepbound have generated over $4 billion in revenue in a single quarter. If Viking can successfully navigate the final stages of development and bring its products to market, even a fraction of the existing market share could lead to significant growth for the company and its investors.

For market professionals, Viking represents a compelling opportunity within the biotech sector. Its potential for rapid stock appreciation, particularly following positive trial results, makes it a noteworthy candidate for growth-oriented portfolios.

Source: fool.com